PDCD1 and neoplasm: T cells that target tumor neoantigens have been suggested to be the main mediators of effective cancer immunotherapies, not only in the context of adoptive T cell therapy, but also for successful treatment with checkpoint modulators against CTLA-4 and PD-1 (18, 19).